JP Morgan Maintains Overweight on CeriBell, Lowers Price Target to $17
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Robbie Marcus maintains CeriBell (NASDAQ:CBLL) with a Overweight and lowers the price target from $21 to $17.
JP Morgan analyst Robbie Marcus maintains CeriBell (NASDAQ:CBLL) with a Overweight and lowers the price target from $21 to $17.